KRISZTINA HEREDI-SZABO, EMESE KIS, EVA MOLNAR, ANDRAS GYORFI, and PETER KRAJCSI MRP2 (ABCC2) is an efflux transporter expressed on the apical membrane of polarized cells. This protein has a major role in the biliary elimination of toxic compounds from the liver. As MRP2 transports many endogenous compounds, including LTC4 as well as xenobiotics and toxic phase II metabolites, blockade of this transporter may cause the accumulation of these compounds in the hepatocyte, resulting in hepatotoxicity. The vesicular transport assay is a great tool to study drug-drug and drug-endogenous compound interactions of ABC transporters. In this assay, inside-out membrane vesicles are used, so the test compound can readily access the transporter. As MRP2 transports many ionic compounds that are difficult to investigate in a whole-cell system because of permeability reasons, the vesicular transport assay is a good choice for screening MRP2-mediated interactions. LTC4 is not an optimal substrate for high-throughput screening for MRP2 interactors, even though it is an important MRP2 substrate. Therefore, the transport of a drug surrogate, 5(6)-carboxy-2,′7′-dichlorofluorescein (CDCF), by MRP2 was characterized using the vesicular transport assay. The data indicate that CDCF proves to be an ideal substrate for MRP2 vesicular transport assay with its optimal detection and transport properties. (Journal of Biomolecular Screening 2008:295-301) 
INTRODUCTION
M RP2 (CMOAT, ABCC2) belongs to the family of ABC transporters. 1 These proteins have a major role in determining pharmacokinetic parameters of drugs by transporting molecules across pharmacologically important barriers. The mechanism of substrate efflux out of the cell is coupled with ATP hydrolysis. 2, 3 MRP2 is localized on the apical membrane of polarized cells 4 in various tissues, such as the liver, 5 intestine, 6 or kidneys. 7 MRP2 is a multispecific organic anion transporter involved in the efflux of many hydrophilic compounds and conjugates, such as glucuronides, glutathiones, and sulfates. 8 Among its natural substrates are hormone conjugates (estradiol glucuronides, E 2 17βG and E 2 3βG), leukotriene C4, bilirubin glucuronides, and dianionic bile salts. Blockade of MRP2 on the canalicular membrane of hepatocytes causes accumulation of these endogenous substrates in the cell. This may occur due to various drugs that interact with MRP2. The same phenomenon is observed in the Dubin-Johnson syndrome, 9 an autosomal recessive genetic disease related to missing MRP2 function. 10 These patients develop conjugated hyperbilirubinemia and increased accumulation of hepatocellular pigment. The reason for the development of hyperbilirubinemia is a rescue mechanism of the hepatocyte, namely, the upregulation of MRP3, 11, 12 a protein with overlapping substrate specificity but alternative cellular localization. 13, 14 MRP3 is expressed on the basolateral membrane of polarized cells and pumps its substrate back to the bloodstream. 13 As many drug metabolites are eliminated through the bile as conjugates, it is advisable to know whether they interact with MRP2. The vesicular transport assay is an in vitro tool to study ABC transporter-related drug-drug and drug-endogenous substrate interactions. [15] [16] [17] [18] [19] The assay uses inside-out vesicles whereby the transporter carries its substrates into the vesicle in the presence of ATP ( Fig. 1) . In the case of low-permeability compounds, the direct transport of the molecule into the vesicle can be observed by using an adequate detection system: Compounds can be labeled with isotopes or fluorescent tags, or the compound itself can be detected using analytical methods such as liquid chromatography-mass spectroscopy. In a different setup, by using a low-permeability reporter substrate ( 3 H-E 2 17βG or 3 H-LTC4, in the case of MRP2), the effect of an unlabeled test compound on the transport of the reporter substrate can be measured. This is the indirect vesicular transport assay, a high-throughput in vitro system that can easily be automated. The main advantage of the vesicular transport assay is that it provides valuable information about the interaction of the test compound with the transporter-mediated efflux of an endogenous substrate. Also, as most of the studied conjugates are hydrophilic and generated inside the cell, they cannot be studied in the regularly used monolayer assays, in case the cells do not have adequate metabolic capabilities or do not express the relevant uptake transporters. In the vesicular transport assay, the hydrophilic conjugate can readily access the transporter. Another important point is that in the widely used monolayer assays, to study the vectorial transport of molecules, it is hard or impossible to estimate the free intracellular concentration of a compound; thus, the affinity of it to the efflux transporter cannot be determined directly. Because of the inside-out orientation of the vesicles used in the vesicular transport assay, the applied drug concentration is basically the same as the intracellular concentration might be. In the case of MRP2, the 2 most commonly used endogenous substrates for vesicular transport assay are LTC4 and E 2 17βG. LTC4 is transported by MRP2 following the classical 1-binding-site model, 20,21 whereas E 2 17βG was shown to recognize 2 different binding sites on MRP2, 15, 22 which manifests as stimulation of E 2 17βG transport in the presence of certain molecules. Even though LTC4 is a common and physiologically important substrate of MRP2, 23 it is not commonly used because of experimental difficulties of 3 H-LTC4.
Fluorescent dyes as transporter substrates offer an alternative way to detect transporter-related interactions. Fluorescent detection is just as sensitive as liquid scintillation but quicker, and the use of radioactive materials can also be avoided. The major difficulty in this approach is to prove that the interactions with the dye provide just as valuable information as the interaction with the endogenous compound itself. By finding fluorescent compounds with similar kinetic behavior to endogenous substrates, a new high-throughput vesicular transport assay can be created after careful validation. 5(6)-carboxy-2,′7′-dichlorofluorescein (CDCF) was chosen for these purposes, as this compound was described previously in the literature, as a substrate of MRP2. 11, [24] [25] [26] Besides, CDCF has good spectroscopic properties and low permeability, ensuring the optimal detection of this compound. In this article, the validation of this fluorescent dye, CDCF, is described as a drug surrogate for MRP2 replacing LTC4.
MATERIALS AND METHODS

Materials
MK571 was purchased from Alexis Corporation (Lausen, Switzerland). 3 H-Leukotriene C4 (LTC4) was purchased from PerkinElmer (Boston, MA, USA). All other chemicals and unlabeled compounds were purchased from Sigma.
Expression of human MRP2 in insect cells
Recombinant baculoviruses encoding the wild-type human MRP2 27 and defective MRP1 mutant G771D (defMRP), 28 used as control throughout the studies, were kind gifts from Drs. Balazs Sarkadi (National Medical Center, Budapest, Hungary) and András Váradi (Institute of Enzymology, Budapest, Hungary). Sf9 cells were cultured and infected with the recombinant baculovirus stocks as described earlier. 27, 29 
Membrane preparation
Membrane vesicle preparations obtained from insect cells expressing ABCC2 (MRP2-Sf9) and defective MRP1 mutant G771D (defMRP-Sf9) were obtained from SOLVO Biotechnology (Szeged, Hungary). Purified membrane vesicles from baculovirusinfected Sf9 cells were prepared essentially as described previously. 30 Membrane protein content was determined using the BCA method (Pierce Biotechnology, Rockford, IL). The presence of the MRP2 transporter was confirmed with Western blot, using the MRP2-specific monoclonal antibody M 2 III-5 (Alexis Corp, Lausen, Switzerland).
Vesicular transport assay
Inside-out membrane vesicles were incubated in the presence or absence of 4 mM ATP. For LTC4 vesicular transport, the measurements were carried out in 7.5 mM MgCl 2 , 40 mM MOPS-Tris, pH 7.0, 70 mM KCl, at 37 °C for 30 s. The transport was stopped by the addition of cold wash buffer (40 mM MOPS-Tris, pH 7.0, 70 mM KCl), and the samples were transferred to class B glass fiber filters, 1-μM pore size (Millipore, Billerica, MA). Filters were washed with 5 × 200 μL of ice-cold wash buffer, and radioactivity retained on the filter was measured by liquid scintillation counting. ATP-dependent transport was calculated by subtracting the values obtained in the absence of ATP from those in the presence of ATP.
For CDCF vesicular transport, the MRP2 PREDIVEZ Kit was used according to the manufacturer's instructions (SOLVO Biotechnology).
Data analysis
Vesicular transport assays were run in duplicates. Data are presented as the mean ± standard deviation. For data analysis, the GraphPad PRISM 4.0 software (GraphPad Software Inc., San Diego, CA) was applied using the following equations.
K m and V max values from direct transport measurements were calculated using the Michaelis-Menten equation after estimating the number of binding sites from the Hill plot:
where V is the velocity (pmol substrate per milligram of protein per minute), V max is the maximal velocity, [S] is the substrate concentration in μM, and K m is the Michaelis-Menten constant.
The results of the indirect vesicular transport assays were analyzed using the Hill equation (variable slope sigmoid equation):
where V is the velocity (pmol substrate per milligram of protein per minute), V min is the minimal velocity (fully inhibited transport), V max is the maximal velocity (in the absence of inhibitor), EC 50 is the ligand concentration producing 50% of the maximal response (efficacy), [A] is the actual test drug concentration, and Hill slope is the parameter characterizing the degree of cooperativity. K I values for the different compounds were determined using the Cheng-Prusoff equation 31 :
where K I is the affinity of the inhibitor, IC 50 is the concentration of the inhibitor that inhibits 50% of the transport, [S] is the concentration of the substrate, and K m is the affinity of the substrate.
RESULTS
Characterization of LTC4 and CDCF transport by MRP2
Both LTC4 and CDCF are transported by MRP2 in a dosedependent manner. Negligible CDCF transport is observed in the case of control vesicles expressing defMRP, whereas the background transport is significant in the case of LTC4 transport (Fig.  2) . The K m values are 694 ± 26 nM and 12.3 ± 0.7 μM, respectively, whereas the V max values are 175 ± 23 pmol/mg protein/min and 40.1 ± 0.7 pmol/mg protein/min, respectively, for LTC4 and CDCF. The slopes of the Hill plots are close to unity for both substrates, indicating the involvement of 1 binding site in the transport of LTC4 and CDCF. LTC4 transport is linear up to 2 min, whereas CDCF transport is linear up to 30 min (Fig. 3) . The transport of both substrates is sensitive to the osmolarity of the buffer, indicating active transport (data not shown).
Inhibition of substrate transport by known MRP2 interactors
Five representative compounds (known MRP2 substrates and inhibitors) were investigated for their abilities to inhibit both LTC4 and CDCF transport in the vesicular transport assay. All compounds inhibited the transport of both LTC4 and CDCF in a dose-dependent manner with similar IC 50 values ( Fig. 4 and Table 1 ).
Validation of the new method using MRP2 interactors from the literature
Twenty compounds that were described to be MRP2 interactors were collected from the literature, and their effect on CDCF transport by MRP2 was compared with the collected data ( Table 2) .
DISCUSSION
LTC4 is a physiologically relevant, high-affinity substrate of MRP2, 36 as this compound and its active metabolites-especially LTE4-are eliminated from the blood through hepatobiliary excretion. 37 It was shown mainly in MRP2-deficient animals 23 and patients with Dubin-Johnson syndrome 38 that only 2% of the normal LTC4 is excreted through the bile, whereas the urinary excretion of leukotrienes is significantly elevated. Insufficient efflux of these proinflammatory compounds from the hepatocytes may cause liver damage.
Despite the importance of this MRP2 substrate, LTC4 is not commonly used in the literature because of technical difficulties in its application for the vesicular transport assay, as our results also demonstrate. Because of the lack of robustness in the case of LTC4 vesicular transport assay, this reporter substrate is
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not optimal for high-throughput screening of compounds for their interactions with MRP2. LTC4 is transported by MRP2 following the classical Michaelis-Menten kinetics (Fig. 2) . A fluorescent drug surrogate, CDCF, with similar kinetic parameters but better detection properties and more convenient assay parameters can be used to model LTC4-like interactions mediated by MRP2 ( Figs. 2  and 4) .
In many cases, high-affinity substrates are transported with low capacity, so the transport is saturated fast. 20, 21 Our findings confirm data from the literature about LTC4 being such a substrate (Fig. 2) . The short reaction time makes the assay inconvenient to work with and also decreases reproducibility. In contrast, transport of CDCF is saturated after only 30 min, which makes the assay more robust. As Table 1 shows, the MRP2-mediated effect of LTC4 and CDCF on the transport of the other substrate was also investigated. The calculated K I values are close to the respective K m values for the 2 substrates, which is an indication that LTC4 and CDCF are transported through the same site of MRP2. The baculovirus-infected Sf9 system is widely used for its ability to produce ABC transporter overexpressing membranes at a high and standard quality. However, it is less known that Sf9 cells express MRP-like endogenous proteins that are able to transport typical MRP substrates. This explains the relatively high LTC4 transport that is observed in the vesicles expressing the defective MRP1 transporter used as a negative control for MRP2-mediated transport studies. This transporter is also able to transport CDCF, but probably at a lesser extent, as the effect of the endogenous transporter is negligible in this case compared with the overall effect ( Fig. 1) . MRP2 can also be expressed stably in cells of mammalian origin, such as LLC-PK1, 22 HEK-293, 39 or MDCKII, 39 in which case the background LTC4 transport is negligible. On the other hand, the mammalian systems usually express less exogenous protein compared with the baculovirus-infected insect cells, so the signal-to-noise ratio of the LTC4 transport is even worse. In this study, we chose the insect system, as this is one that is widely used and also commercially available.
Heredi
Twenty compounds were investigated for their effect on CDCF transport by MRP2, and the results were compared to data from the literature ( Table 2) . As CDCF is not used widely as a reporter substrate in the MRP2 vesicular transport assay, we compared the calculated K I values obtained to similar parameters gained from vesicular transport assays using other reporter substrates, such as methotrexate or E 2 17βG. Methotrexate is a lowaffinity substrate of MRP2 with a K m in the millimolar range, and as our results demonstrate, the IC 50 value for methotrexate in the CDCF assay is also in the same range ( Table 2) . This may be an indication that CDCF and methotrexate share the same binding site on MRP2. E 2 17βG transport by MRP2 follows different kinetics from that of CDCF, and based on our results, the maximal stimulatory concentration of E 2 17βG transport by a compound often correlates with its IC 50 /K I value obtained from the CDCF assay.
Our results demonstrate that by combining an in vitro highthroughput system, the vesicular transport assay, and a reporter substrate with optimal detection and transport properties, an excellent tool for the investigation of MRP2-mediated interactions can be created. This assay, commercialized as the MRP2 PREDIVEZ Kit, was able to detect all of the interactions listed in Table 2 . The reasons for the discrepancies might include differences in the assay systems used in the different laboratories. a. Data are presented as the mean ± standard deviation. CDCF = 5(6)-carboxy-2,′7′-dichlorofluorescein; MTX = methotrexate; VT = vesicular transport; CMV = canalicular membrane vesicle.
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